RxDoctor Payments Data

Susan Ignatius, MD

Internal Medicine · Carol Stream, ILNPI 1649374935

Payments from drug & device makers

$2,275in general payments, 2019–2025

Across 24 payments — averaging $94.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$604
  • Lilly USA, LLC$571
  • AbbVie$308
  • Amgen$228
  • Dexcom, Inc.$216
  • Boehringer Ingelheim$210
  • plus $138 from 2 others

What the payments were for

  • Food & beverage$2,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$604
Lilly USA, LLC7$571
AbbVie3$308
Amgen2$228
Dexcom, Inc.2$216
Boehringer Ingelheim2$210
Novartis1$123
Abbott1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,275 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$299,888
Medicare patients
533
Services billed
3,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin147$136,528
EliquisApixaban78$89,672
OzempicSemaglutide51$59,133
XareltoRivaroxaban39$44,516
Breo ElliptaFluticasone/Vilanterol78$36,761
JanuviaSitagliptin Phosphate26$31,782
MounjaroTirzepatide30$31,678
TrulicityDulaglutide19$24,582
TradjentaLinagliptin17$17,563
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,445
DuleraMometasone/Formoterol33$11,434
Atorvastatin Calcium811$8,028
Fluticasone-SalmeterolFluticasone Propion/Salmeterol82$7,463
Labetalol Hcl187$7,445
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$7,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$210$154,090164 claims
Novo NordiskOzempic$604$59,13351 claims
Lilly USA, LLCMounjaro, Trulicity$571$56,26049 claims
AbbVieSynthroid$308$6,17282 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Carol Stream

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →